The Role of Revefenacin in Chronic Obstructive Pulmonary Disease
| Autor: | Muhammad Haisum Maqsood, Muhammad Arqam Maqsood, Kinza Rubab |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Spirometry
Pulmonology 030204 cardiovascular system & hematology Placebo chronic obstructive pulmonary disease 03 medical and health sciences 0302 clinical medicine Internal Medicine medicine Potency Dosing Adverse effect COPD medicine.diagnostic_test business.industry General Engineering Muscarinic antagonist copd Muscarinic acetylcholine receptor M2 medicine.disease revefenacin Anesthesia Public Health business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.4428 |
| Popis: | Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by progressive and persistent airflow limitation that is not fully reversible. Revefenacin is an investigational long-acting muscarinic antagonist (LAMA), in late-stage development as a nebulized inhalation solution, which has been designed to produce long-acting bronchodilation, consistent with once-daily dosing, and with a high degree of lung-selectivity. It is more selective for muscarinic type 3 (M3) than muscarinic type 2 (M2) or muscarinic type 1 (M1) receptors. Its dissociation half-life for M3 is 82 minutes and 6.9 minutes for M1, respectively. The bronchoprotective effect is seen as early as five-minute post-dose and is sustained for up to 24 hours. The estimated 24-hour potency (expressed as the concentration of dosing solution) is 45.0 mg/ml. Once-daily dose of revefenacin provided long-term improvement in trough forced expiratory volume in one second (FEV1). It improved day 28 trough FEV1 over placebo significantly (p < 0.001). M3: M2 receptor half-life is 12 compared to the other antagonists that have M3: M2 receptor half-life around 6.0. A 24-hour serial spirometry, on day 84, showed that revefenacin 88 or 175 µg was associated with significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|